2025
An estimated 0 designations were granted, and 0 priority review vouchers were awarded.
0 vouchers were sold for a total of $0 million.
Planting the seeds of rare disease research
The FDA's Rare Pediatric Disease Designation Priority Review Voucher Program has planted the seeds for 59 new rare disease treatments, with 55 first-ever therapies blooming where none existed before. Despite 2024 being its most fruitful year, Congress failed to renew the program at the end of the year. Now it is imperative that we join our voices together to demand that elected officials allow this garden of hope to continue to flourish.